NCT06189209 2025-12-02
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Rhizen Pharmaceuticals SA
Phase 2 Recruiting
Clinical Trials
5 trialsNCT04204057 2024-08-13
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Rhizen Pharmaceuticals SA
Phase 2 Completed
NCT05021900 2024-08-13
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Rhizen Pharmaceuticals SA
Phase 2 Completed
NCT05239910 2022-10-17
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Rhizen Pharmaceuticals SA
Phase 2 Withdrawn
NCT03711578 2021-08-12
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Rhizen Pharmaceuticals SA
Phase 2 Completed